US 12,168,061 B2
Antibody against glypican-3 and application thereof
Huamao Wang, Shanghai (CN); and Bo Song, Shanghai (CN)
Assigned to CRAGE MEDICAL CO., LIMITED, Hongkong (CN)
Appl. No. 15/750,271
Filed by CRAGE MEDICAL CO., LIMITED, Hong Kong (CN)
PCT Filed Aug. 2, 2016, PCT No. PCT/CN2016/092833
§ 371(c)(1), (2) Date Feb. 5, 2018,
PCT Pub. No. WO2017/020812, PCT Pub. Date Feb. 9, 2017.
Claims priority of application No. 201510481235.1 (CN), filed on Aug. 3, 2015.
Prior Publication US 2019/0046659 A1, Feb. 14, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61K 48/00 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); C07K 19/00 (2006.01); C12N 5/10 (2006.01); C12N 15/62 (2006.01); C12N 15/63 (2006.01); G01N 33/574 (2006.01)
CPC A61K 47/6879 (2017.08) [A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61K 39/395 (2013.01); A61K 48/00 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/7151 (2013.01); C07K 16/2809 (2013.01); C07K 16/30 (2013.01); C07K 16/303 (2013.01); C07K 16/46 (2013.01); C07K 19/00 (2013.01); C12N 5/10 (2013.01); C12N 15/62 (2013.01); C12N 15/63 (2013.01); A61K 2039/5156 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); G01N 33/57438 (2013.01)] 26 Claims
 
1. An antibody that specifically recognizes glypican-3, comprising within an antibody molecule:
a light chain variable region comprising VL CDR1 having the sequence of SEQ ID NO: 16, VL CDR2 having the sequence of SEQ ID NO: 18, and VL CDR3 having the sequence of SEQ ID NO: 20; and a heavy chain variable region comprising VH CDR1 having the sequence of SEQ ID NO: 10, VH CDR2 having the sequence of SEQ ID NO: 12, and VH CDR3 having the sequence of SEQ ID NO: 14.